Printer Friendly

Lantheus reports 'positive' Phase 2 LMI 1195 trial data.

Lantheus Holdings announced "positive" new data from a Phase 2 study of LMI 1195, a fluorine-18 labeled tracer for use in cardiac positron emission tomography to assess myocardial presynaptic sympathetic nerve function. Altered sympathetic nervous system function has been implicated in a broad range of clinical conditions including heart failure and sudden death. The data will be presented during a poster presentation at the American College of Cardiology's 67th Annual Scientific Session on Monday, March 12, 2018 at 9:45 a.m. ET in the Noninvasive Imaging Moderated Poster Theater. The data show that PET imaging with LMI 1195 provides a comparable measure of cardiac sympathetic nerve function and more favorable kinetics for early cardiac imaging as PET imaging with carbon-11 hydroxyephedrine. C11 HED has been used in cardiac PET imaging to characterize SNS integrity and risk-stratify patients with ischemic cardiomyopathy considered for implantable cardiac defibrillators. However, widespread clinical utility is limited due to the short half-life of C11-labeled tracers, which require the onsite availability of a cyclotron. The findings suggest that LMI 1195 yields a comparable estimate of cardiac sympathetic innervation as C11 HED. LMI 1195 retention index and defect score correlated highly with HED. LV-to-lung ratios were comparable between the two tracers. In addition, LMI 1195 seems to offer more favorable kinetics for early cardiac imaging than HED. A significant difference in blood clearance was observed between the two tracers resulting in a LV-to-blood ratio of LMI-1195 higher than HED within the first five minutes following administration.

COPYRIGHT 2018 The Fly
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:The Fly
Date:Mar 12, 2018
Words:249
Previous Article:Sino-Global raises $3M in a registered direct offering.
Next Article:Insulet announced coverage win with UnitedHealth, says William Blair.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters